Antibody against calcified globule and use of the same
AssigneesNational University Corporation Okayama University, Medical & Biological Laboratories Co., Ltd.
InventorsEiji Matsuura, Hiromi Kumon, Kazuo Kojima
Life of this patent
Estimating the term…
Abstract
The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.
Claims16
An isolated antibody which is reactive to a calcified globule (NLO) derived from renal or urinary calculi and has the activity of binding to an atherosclerotic plaque, which is the antibody of any one of (e), (j), or (o):
- (a) an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 1, CDR2 having the amino acid sequence of SEQ ID NO:
- 2, and CDR3 having the amino acid sequence of SEQ ID NO:
- 3;
- (b) an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO:
- 4;
- (c) an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 6, CDR2 having the amino acid sequence of SEQ ID NO:
- 7, and CDR3 having the amino acid sequence of SEQ ID NO:
- 8;
- (d) an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO:
- 9;
- (e) an antibody that comprises a pair of the heavy chain of (a) or (b) and the light chain of (c) or (d);
- (f) an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 11, CDR2 having the amino acid sequence of SEQ ID NO:
- 12, and CDR3 having the amino acid sequence of SEQ ID NO:
- 13;
- (g) an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO:
- 14;
- (h) an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 16, CDR2 having the amino acid sequence of SEQ ID NO:
- 17, and CDR3 having the amino acid sequence of SEQ ID NO:
- 18;
- (i) an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO:
- 19;
- (j) an antibody that comprises a pair of the heavy chain of (f) or (g) and the light chain of (h) or (i);
- (k) an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 21, CDR2 having the amino acid sequence of SEQ ID NO:
- 22, and CDR3 having the amino acid sequence of SEQ ID NO:
- 23;
- (l) an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO:
- 24;
- (m) an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 26, CDR2 having the amino acid sequence of SEQ ID NO:
- 27, and CDR3 having the amino acid sequence of SEQ ID NO:
- 28;
- (n) an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO:
- 29;
- (o) an antibody that comprises a pair of the heavy chain of (k) or (l) and the light chain of (m) or (n).
An agent for inhibiting the growth of a calcified globule, which comprises an isolated antibody that comprises:
- a heavy chain of either an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 21, CDR2 having the amino acid sequence of SEQ ID NO:
- 22, and CDR3 having the amino acid sequence of SEQ ID NO:
- 23;
- or an antibody comprising a heavy-chain variable region having the amino acid sequence of SEQ ID NO:
- 24;
- and
- a light chain of either an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO:
- 26, CDR2 having the amino acid sequence of SEQ ID NO:
- 27, and CDR3 having the amino acid sequence of SEQ ID NO:
- 28;
- or an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO:
- 29.
Dependencies are inferred from the claim text.